Risk Factors for Psychosis in Parkinson’s Disease
Psychosis is a characteristic neuropsychiatric symptom of Parkinson’s disease (PD) that is common and associated with worse outcomes. The purpose of this article is to review identified risk factors for visual hallucinations in PD, the most common manifestation of psychosis. With the possible exception of dopamine agonists, antiparkinsonian medications are only considered modifiers of psychosis in PD. Dementia in PD has consistently been shown to be associated with psychosis, and executive dysfunction and impairment in visual processing appear to play a role in its pathogenesis. The association of psychosis with disorders of sleep–wake dysregulation and autonomic dysfunction supports the involvement of brainstem dysfunction in PD psychosis. Despite many studies evaluating genetic risk factors for hallucinations, GBA mutations are the only variants consistently reported to be associated with an increased risk of hallucinations in PD. Lastly, psychosis in PD is associated with a more severe disease burden, both related and unrelated to PD pathology. Any explanatory model of psychosis in PD must incorporate pharmacological, neuroanatomic, pathological, and genetic factors before there can be a complete understanding of this common and disabling neuropsychiatric symptom.
Parkinson’s disease, psychosis, hallucinations, risk factor, dementia, rapid eye movement (REM) sleep behavior disorder
Matthew J Barrett has received grant support from the Department of Defense and the Commonwealth of Virginia’s Alzheimer’s and Related Diseases Research Award Fund and has served as site primary investigator for clinical trials funded by the National Institutes of Health, Azevan, Axovant, and Merck. No funding was received in the publication of this article.
Authorship: All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship of this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval to the version to be published.
Matthew J Barrett, University of Virginia, Department of Neurology, PO Box 800394, Charlottesville, VA 22908, US. E: firstname.lastname@example.org
This article is published under the Creative Commons Attribution Noncommercial License, which permits any non-commercial use, distribution, adaptation and reproduction provided the original author(s) and source are given appropriate credit.
Share this Article
Related Content In Psychiatric Disorders
Emerging Perspectives in the Management of Agitation in Alzheimer’s Disease and Patients with Dementia
touchREVIEWS in Neurology. 2022;18(1):7–13 DOI: https://doi.org/10.17925/USN.2022.18.1.7
While Alzheimer’s disease (AD), the most common cause of dementia, is perhaps best characterized by cognitive decline, more than 90% of patients with dementia exhibit behavioural and psychological symptoms of dementia.1 The Cache County Study on Memory in Aging describes six areas of neuropsychiatric behavioural abnormalities in patients with AD and other dementias, comprising aggression, apathy, […]
GABA-A Receptor Positive Allosteric Modulators as a Novel Approach to Treating Depression: A Review of Available Data
touchREVIEWS in Neurology 2021;17(2):77–84 DOI: https://doi.org/10.17925/USN.2021.17.2.77
Postpartum depression (PPD) is an important mental health problem that is associated with maternal distress and poor maternal–fetal bonding. The Diagnostic and Statistical Manual of Mental Disorders (DSM-5) now classifies PPD as major depressive disorder (MDD), with peripartum onset.1 The distinction ‘with peripartum onset’ is new in DSM-5 and is important, as 50% of ‘postpartum’ major […]
Emerging Perspectives in the Diagnosis and Management of Depression and Psychosis in Parkinson’s Disease
touchREVIEWS in Neurology. 2021;17(2):97–103 DOI: https://doi.org/10.17925/USN.2021.17.2.97
Parkinson’s disease (PD) is a progressive, neurodegenerative movement disorder and the second most common neurodegenerative disorder in the United States.1 In 2020, approximately 930,000 people in the United States aged 45 years and older developed the disease, and this number is expected to rise to 1,238,000 by 2030.2 The typical age of onset is around 60 years, […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!